Enanta Pharmaceuticals. has filed a patent for a process to produce a compound (Formula A) that can be used as a SARS-CoV-2 3CL pro inhibitor. The compound and its pharmaceutical compositions have potential applications in the treatment of COVID-19. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Enanta Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Process for producing a sars-cov-2 3cl pro inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Enanta Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230295175A1) describes a process for producing a compound of Formula (A). The process involves several steps and conditions, as outlined in the claims.

In the first claim, the process for producing the compound is described. The subsequent claims provide additional details and variations of the process. For example, claim 2 specifies that when R1 is F (fluorine) and R2 is isobutyl, the process is conducted. Claim 3 further specifies that when G1 is methyl, X is Cl- (chloride ion), and PG1 is Cbz (carbobenzyloxy), the process is conducted.

The claims also outline the specific conditions and reagents used in each step of the process. For example, in step (b), the reaction is conducted in the presence of di-tert-butyl dicarbonate (Boc anhydride) as a Boc protection reagent and triethylamine as a base. In step (c), the reaction is conducted in the presence of N-bromosuccinimide (NBS), acetic acid, at a temperature of about -30° C., and the ratio of diastereomer (d-1) to diastereomer (d-2) is from 6:1 to 8:1. Similar details are provided for the other steps of the process.

Claims 5 to 8 and claims 9 to 11 describe alternative processes for producing the compound of Formula (A) with variations in the reagents and conditions used in each step.

Overall, the patent claims describe a detailed process for producing a compound of Formula (A) with specific variations and conditions. The process involves multiple steps and the use of various reagents and catalysts. The claims provide a comprehensive overview of the process and its variations, allowing for potential applications in the field.

To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies